Q-omics provides the consensus-scored PPP2R5A profile across patient tissues and cancer cell-line models. PPP2R5A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PPP2R5A is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, PPP2R5A protein abundance shows 29,651 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, and LUAD as cancer lineages where PPP2R5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP2R5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP2R5A survival associations across molecular data types. PPP2R5A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP2R5A RNA expression–survival associations across cancer types. High PPP2R5A expression shows unfavorable associations in ACC, KIRP, READ and UVM, but favorable associations in KIRC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PPP2R5A RNA expression.
This table summarizes PPP2R5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 12. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PPP2R5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP2R5A shows lower tumor expression in KIRC, LUAD, BLCA, LUSC and COAD and higher tumor expression in LIHC. The KIRC box plot shows higher PPP2R5A RNA expression in normal versus tumor tissue (log2 FC = −0.610, t-test p < 0.001).
This table shows molecular features associated with PPP2R5A in patient tissues and cancer cell lines. In patient samples, PPP2R5A shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP2R5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
